[
  {
    "ts": null,
    "headline": "Merck Provides Update on KeyVibe and KEYFORM Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab Fixed-Dose Combinations with Pembrolizumab",
    "summary": "RAHWAY, N.J., December 16, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the discontinuation of the clinical development programs for vibostolimab, an anti-TIGIT antibody, and favezelimab, an anti-LAG-3 antibody. Vibostolimab is being evaluated as an investigational fixed-dose combination with pembrolizumab (KEYTRUDA®) in the KeyVibe program. Favezelimab is being evaluated as an investigational fixed-dose combination with pembrolizumab in the KEYF",
    "url": "https://finnhub.io/api/news?id=24fd78a6828ad9ea0e154e3dee40ab16554a8a84e1f4e0e6f5acf092a1d26d57",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734384600,
      "headline": "Merck Provides Update on KeyVibe and KEYFORM Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab Fixed-Dose Combinations with Pembrolizumab",
      "id": 132018844,
      "image": "https://media.zenfs.com/en/business-wire.com/55060e0a6e0b05a55ea88b62c905a317",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., December 16, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the discontinuation of the clinical development programs for vibostolimab, an anti-TIGIT antibody, and favezelimab, an anti-LAG-3 antibody. Vibostolimab is being evaluated as an investigational fixed-dose combination with pembrolizumab (KEYTRUDA®) in the KeyVibe program. Favezelimab is being evaluated as an investigational fixed-dose combination with pembrolizumab in the KEYF",
      "url": "https://finnhub.io/api/news?id=24fd78a6828ad9ea0e154e3dee40ab16554a8a84e1f4e0e6f5acf092a1d26d57"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock outperforms competitors despite losses on the day",
    "summary": "Merck & Co. Inc. stock outperforms competitors despite losses on the day",
    "url": "https://finnhub.io/api/news?id=b39ec00d58268c277141b7d7eff8a995adb451f72925d99b26d345407cc37e00",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734366900,
      "headline": "Merck & Co. Inc. stock outperforms competitors despite losses on the day",
      "id": 132065119,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=b39ec00d58268c277141b7d7eff8a995adb451f72925d99b26d345407cc37e00"
    }
  },
  {
    "ts": null,
    "headline": "Merck’s KEYTRUDA® (pembrolizumab) Approved in China in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy After Surgery as Adjuvant Treatment for Patients With Resectable Stage II, IIIA or IIIB NSCLC",
    "summary": "RAHWAY, N.J., December 16, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced KEYTRUDA, Merck’s anti-PD-1 therapy, has been approved by the National Medical Products Administration (NMPA) in China in combination with platinum-containing chemotherapy as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment after surgery for patients with resectable stage II, IIIA, or IIIB non-small cell lung cancer (NSCLC).",
    "url": "https://finnhub.io/api/news?id=51148a499ce81d8085c31acb54dd8e5d8c3c8e1707d588d093b18afd0b7be4bd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734349500,
      "headline": "Merck’s KEYTRUDA® (pembrolizumab) Approved in China in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy After Surgery as Adjuvant Treatment for Patients With Resectable Stage II, IIIA or IIIB NSCLC",
      "id": 132012888,
      "image": "https://media.zenfs.com/en/business-wire.com/18fb22972e5bd41c4a9830cf186549ba",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., December 16, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced KEYTRUDA, Merck’s anti-PD-1 therapy, has been approved by the National Medical Products Administration (NMPA) in China in combination with platinum-containing chemotherapy as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment after surgery for patients with resectable stage II, IIIA, or IIIB non-small cell lung cancer (NSCLC).",
      "url": "https://finnhub.io/api/news?id=51148a499ce81d8085c31acb54dd8e5d8c3c8e1707d588d093b18afd0b7be4bd"
    }
  },
  {
    "ts": null,
    "headline": "Merck Receives Positive EU CHMP Opinion for WELIREG as Treatment for Adult Patients with Certain Types of Von Hippel-Lindau Disease-Associated Tumors and for Certain Previously Treated Adult Patients with Advanced Renal Cell Carcinoma",
    "summary": "RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion...",
    "url": "https://finnhub.io/api/news?id=445473ed2d6f75c35c17174eae99b24d753c84d6a08373be69580adbf5e0d608",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734346993,
      "headline": "Merck Receives Positive EU CHMP Opinion for WELIREG as Treatment for Adult Patients with Certain Types of Von Hippel-Lindau Disease-Associated Tumors and for Certain Previously Treated Adult Patients with Advanced Renal Cell Carcinoma",
      "id": 132012077,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion...",
      "url": "https://finnhub.io/api/news?id=445473ed2d6f75c35c17174eae99b24d753c84d6a08373be69580adbf5e0d608"
    }
  },
  {
    "ts": null,
    "headline": "Dow's 115-point rally highlighted by gains in Honeywell, Nike shares",
    "summary": "Dow's 115-point rally highlighted by gains in Honeywell, Nike shares",
    "url": "https://finnhub.io/api/news?id=4a1fea4c4978cda8d6421ec6d1e412f0251d8b038b59fea36fa67ecda7e5fa1f",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734343680,
      "headline": "Dow's 115-point rally highlighted by gains in Honeywell, Nike shares",
      "id": 132065120,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Dow's 115-point rally highlighted by gains in Honeywell, Nike shares",
      "url": "https://finnhub.io/api/news?id=4a1fea4c4978cda8d6421ec6d1e412f0251d8b038b59fea36fa67ecda7e5fa1f"
    }
  },
  {
    "ts": null,
    "headline": "Merck: Keytruda indication expanded in China",
    "summary": "Merck announces that its Keytruda treatment has been approved by the Chinese authorities in combination with platinum-based chemotherapy for patients with resectable stage II, IIIA or IIIB non-small...",
    "url": "https://finnhub.io/api/news?id=3147424ceb242734b84cf41694c2c8f53b47951b2ee6e351d6e9ac39c25302d9",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734337464,
      "headline": "Merck: Keytruda indication expanded in China",
      "id": 132010660,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck announces that its Keytruda treatment has been approved by the Chinese authorities in combination with platinum-based chemotherapy for patients with resectable stage II, IIIA or IIIB non-small...",
      "url": "https://finnhub.io/api/news?id=3147424ceb242734b84cf41694c2c8f53b47951b2ee6e351d6e9ac39c25302d9"
    }
  },
  {
    "ts": null,
    "headline": "Altimmune 2025: Redefining Obesity And MASH Treatment",
    "summary": "Altimmune is redefining success in both obesity and MASH to position Pemvidutide in blue ocean categories. Read why I rate ALT stock a Buy now.",
    "url": "https://finnhub.io/api/news?id=ed55edde371bee8c7944e37ff4cd9da32bc43eb73ae413bbe17d330bbcac6d71",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734318863,
      "headline": "Altimmune 2025: Redefining Obesity And MASH Treatment",
      "id": 132008513,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1359132436/image_1359132436.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Altimmune is redefining success in both obesity and MASH to position Pemvidutide in blue ocean categories. Read why I rate ALT stock a Buy now.",
      "url": "https://finnhub.io/api/news?id=ed55edde371bee8c7944e37ff4cd9da32bc43eb73ae413bbe17d330bbcac6d71"
    }
  },
  {
    "ts": null,
    "headline": "Merck Has Become Very Cheap Again",
    "summary": "Merck has become inexpensive again and combines a good growth outlook with a nice and growing dividend. Learn why MRK stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=a59f4ae8323b85e97c28502df588c3d06fc7f7bcdd02cac7e69b579e79bef734",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734309328,
      "headline": "Merck Has Become Very Cheap Again",
      "id": 132007561,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210931291/image_1210931291.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Merck has become inexpensive again and combines a good growth outlook with a nice and growing dividend. Learn why MRK stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=a59f4ae8323b85e97c28502df588c3d06fc7f7bcdd02cac7e69b579e79bef734"
    }
  }
]